Giant Axonal Neuropathy Pipeline Analysis Report 2021 – Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm
The Giant Axonal Neuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Giant Axonal Neuropathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Giant Axonal Neuropathy with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Giant Axonal Neuropathy Treatment.
-
Giant Axonal Neuropathy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Giant Axonal Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Giant Axonal Neuropathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Giant Axonal Neuropathy Therapeutics Landscape
Globally, only a limited number of companies are involved in the development of novel treatment options for Giant Axonal Neuropathy. This might be due to the difficulty in studying GAN, given its inherent heterogeneity and challenges related to the evaluation of ablation, and may be due to its extremely rare nature. However, the dynamics of the GAN market might change in the coming years.
At present, Taysha Gene Therapies is involved in the development of a pharmaceutical agent for this rare Disorder.
Taysha Gene Therapies is currently evaluating TSHA-120 (Phase I/II), an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health (NIH) in close collaboration with a leading patient advocacy group (Hannah’s Hope) focused on finding treatments and cures for GAN.
Download Sample Pages @ https://www.delveinsight.com/sample-request/giant-axonal-neuropathy-gan-pipeline-insights
Table of Content
1. Report Introduction
2. Giant Axonal Neuropathy
3. Giant Axonal Neuropathy Current Treatment Patterns
4. Giant Axonal Neuropathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Giant Axonal Neuropathy Late Stage Products (Phase-III)
7. Giant Axonal Neuropathy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Giant Axonal Neuropathy Discontinued Products
13. Giant Axonal Neuropathy Product Profiles
14. Giant Axonal Neuropathy Key Companies
15. Giant Axonal Neuropathy Key Products
16. Dormant and Discontinued Products
17. Giant Axonal Neuropathy Unmet Needs
18. Giant Axonal Neuropathy Future Perspectives
19. Giant Axonal Neuropathy Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/giant-axonal-neuropathy-gan-pipeline-insights
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
